miR-144 Potentially Suppresses Proliferation and Migration of Ovarian Cancer Cells by Targeting RUNX1

Shichao Han*
Jinming Zhu*
Yilei Zhang

* These Authors contributed equally to the work

Corresponding Author: Shichao Han, e-mail: HanDong789@163.com
Source of support: Departmental sources

Background: Ovarian cancer (OC) is one of the most common malignant diseases of the female reproductive system worldwide. Evidence has shown that microRNAs are involved in the development of ovarian cancer. miR-144, one of these microRNAs, has been found have upregulated expression in various human malignancies. The present study aimed to investigate the role miR-144 in ovarian cancer cell lines and to elucidate the mechanism involved.

Material/Methods: Human ovarian cancer cell lines (SKOV3/OVCAR3) and a normal ovarian cell line (IOSE80) were used to identify the miR-144 expression though qRT-PCR method. SKOV3/OVCAR3 cells were transfected with miR-144 mimics by Lipofectamine, and the proliferation, migration, and invasion ability of these cells were detected by MTT assay, wound healing assay, and Transwell assays, respectively. MMP2 and MMP9 expression were detected at mRNA and protein levels. The results of dual luciferase reporter assay confirmed that miR-144 could downregulate RUNX1 expression level. Finally, the expression of runt-related transcription factor 1 (RUNX1) was examined using qRT-PCR and Western blot analysis.

Results: Our results demonstrate that the expression level of miR-144 was downregulated in SKOV3/OVCAR3 compared to IOSE80, and we found that miR-144 suppresses the proliferation and migration of ovarian cancer cells. Moreover, RUNX1 was predicted and confirmed to be a target of miRNA-144. Additionally, after 48-h transfection with miR-144 mimics, the expression of RUNX1 was downregulated in OC cells.

Conclusions: miR-144 mimics can inhibit the proliferation and migration of ovarian cancer cells though regulating the expression of RUNX1.

MeSH Keywords: Genes, Tumor Suppressor • MicroRNAs • Ovarian Neoplasms

Full-text PDF: https://www.basic.medscimonit.com/abstract/index/idArt/907333
Background

Ovarian carcinoma (OC) is a highly lethal gynecologic malignancy occurring worldwide. As the fifth leading cause of cancer-related deaths among women, OC accounts for over 140,000 deaths annually [1]. The prognosis of patients with OC is poor and the 5-year survival rate is just 35–38% [2,3]. Hence, great efforts need to be made to identify key molecules involved in the pathogenesis of OC, which could serve as potential therapeutic targets.

MicroRNAs (miRNAs) are small, non-coding RNA molecules (about 22 nucleotides) that function in RNA silencing and post-transcriptional regulation of gene expression [4,5]. Accumulating evidence suggests miRNAs can be used as diagnostic and prognostic biomarkers of many types of cancer. Multiple miRNAs have been reported to regulate tumor cell proliferation, migration, and invasion in ovarian cancer.

MicroRNA-144 (miR-144) is a highly conserved miRNA that participates in the process of tumor genesis and development in liver, lung, breast, and prostate cancers [6,7]. In addition, it has been confirmed to serve as a potential tumor suppressor or oncogene in multiple human cancers. In nasopharyngeal cancer, miR-144 expression was aberrantly upregulated [8], but it functions as a tumor suppressor in gastric cancer [9]. The biological characteristics and targets of miR-144 in ovarian cancer are not well understood. RUNX1 (Runt-related transcription factor 1) is a member of the RUNX transcription factor family and has been found to play an important role in tumor progression. Additionally, it functions as a suppressor or oncogene in various cancers. Potential binding sites for RUNX1 are present in the 5′-flanking region of the miR-144 gene. In our present study, we explored the role and potential mechanisms of miR-144 in ovarian cancer, confirming that miR-144 suppresses the migration, proliferation, and invasion of ovarian cancer cells. We hypothesized that it may function as a suppressor though its target gene, RUNX1.

Material and Methods

Cell lines and cultures

Human ovarian cancer cells (SKOV3/OVCAR3) and a human ovarian surface epithelial cell line (IOSE80) were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum. Cultures were maintained in a humidified atmosphere at 37°C and 5% CO₂.

Cell transfection

We first confirmed the transfection of MiR-144 mimics for SKOV3 and OVCAR3 cell lines using Lipofectamine® RNAiMAX (Invitrogen Thermo scientific, Carlsbad, CA, USA). miR-144 mimics were purchased from Shanghai Gene Pharma (Shanghai, China). miR-144 mimics or empty vector (negative control, NC) were transfected SKOV3/OVCAR3 cells according to the manufacturer’s instructions. The cell lines were divided into 3 groups: the normal group, the miR-144 transfected group, and the negative group, which was transfected with empty vector. Then, transfection efficiencies were determined after 48 h by using qRT-PCR method.

Quantitative real-time PCR (qRT-PCR)

Total RNA was isolated from harvested cells using Trizol Reagents (Invitrogen, USA) according to the manufacturer’s protocol. PrimeScript™ RT reagent Kit was used as well. To measure the expression of miR-144, RUNX1, and MMPs (MMP2, MMP9), quantitative real-time PCR was performed on the StepOne™ Real-Time PCR System (Applied Biosystems Life Technologies, Foster City, CA, USA), and Maxima® SYBR Green/ROX qPCR Master Mix (2X) (Thermo Fisher Scientific, Pittsburgh, PA, USA) was used. The expressions of U6 and GAPDH were used as the internal standard to normalize the miR-144, RUNX1, and MMPs (MMP2 and MMP9) expression levels.

Cell proliferation assay

For the cell proliferation assay, SKOV3/OVCAR3 cells were plated into 96-well plates at a density of 2×10⁴ cells at 200 μl/well, and cultured for 48 h at 37°C. The Vybrant® MTT Cell Proliferation Assay Kit (Invitrogen Thermo scientific, Carlsbad, CA, USA) was used 48 h after transfection according to the manufacturer’s protocol. At different time points (24, 48, and 72 h), 20 μl MTT (5 mg/ml) was added to each well and incubated for an additional 4 h at 37°C. Finally, dimethyl sulfoxide (DMSO, Sigma, USA) was added to stop the reaction, and the absorbance was detected using a microplate reader (Thermo Fisher Scientific, Inc.).

Cell migration and invasion assays

To determine the cell migration and invasion potential, wound healing assay and Transwell assays were performed 48 h after transfection. For the wound healing assay, we seeded SKOV3/OVCOR3 cells in 6-well plates and cultured them until confluent. Then, the cell monolayer was wounded with a yellow pipette tip. Finally, the cells were cultured and observed at 0 and 24 h. For the Transwell assay, SKOV3/OVCOR3 cells were harvested and suspended in medium containing 1% FBS. Cell suspensions were then plated into the upper chamber, and the lower
chamber was filled with culture media. After 24-h incubation, cells were removed from the 24-well plates and stained with Diff-Quick solution. We scraped off the non-invaded cells on the top of the Transwell with a cotton swab. Finally, we counted the invaded cells under a light microscope.

**Dual luciferase reporter assay**

RUNX1 was identified as a miR-144 target in Target Scan 7.1 software (http://www.targetscan.org/vert_71/). Wild-type (Wt) human RUNX1 3’-UTR and mutated (Mut) RUNX1 3’-UTR were synthesized and cloned into the plasmid (Promega, USA). Next, they were transfected with miR-144 mimics or miR-NC mimics using Lipofectamine 2000 (Invitrogen). After 48 h, the relative luciferase activity was calculated by normalizing Firefly luminescence to that of Renilla using the Dual Luciferase Reporter Assay System (Promega, USA).

**Western blot analysis**

Cells were harvested and lysed by RAPI buffer (Beyotime, Shanghai, China), and then were incubated on ice for 30 min. The BCA kit (Beyotime, Shanghai, China) was used to quantify the concentration of protein. Then, the protein was separated with 10% SDS-PAGE and transferred onto polyvinylidene fluoride (PVDF) membranes and incubated with the primary antibodies (anti-RUNX1, anti-MMP2 and anti-MMP9, 1: 1000, Abcam, Cambridge, MA, USA; GAPDH, 1: 1000, Santa Cruz Biotechnology, Inc., USA) overnight at 4°C. The second antibody (purchased from Beyotime, Shanghai, China) used in this study was incubated at 37°C for 1 h. Finally, membranes were incubated with BeyoECL Plus (Beyotime, Shanghai, China), and detected using the ChemiDoc™ XRS+ imaging system (Bio-Rad, California, USA).

**Statistical analysis**

All statistical analyses were carried out using GraphPad Prism software version 5.0. Each experiment was performed at least 3 times. Then Student’s t-test was used to measure the statistical significance of differences between the experimental and control groups. Values are presented as the mean ± standard deviation (SD). P<0.05 was considered as statistical significance.

**Results**

**Expression of miR-144 is downregulated in ovarian cancer cell lines**

To confirm the involvement of miR-144 in ovarian cancer, miR-144 expression was detected in 2 human ovarian cancer cell lines (SKOV3/OVCAR3) and a normal ovarian cell line (IOSE80) by qRT-PCR. Expression levels of miR-144 were significantly lower in the 2 ovarian cancer cell lines compared to IOSE80 (Figure 1A). Then, SKOV3/OVCAR3 cells were transfected with miR-NC and miR-144 mimics. Following qRT-PCR analysis, the results showed that the expression level of miR-144 was significantly upregulated compared with that of miR-NC and NC cells (Figure 1B, 1C).

**miR-144 affected the proliferation, migration, and invasion of OC cells in vitro**

Subsequently, the viability abilities of SKOV3/OVCAR3 cells were detected using the methods, described above. Results from MTT assay demonstrated that both tested cells lines transfected with the miR-144 mimic were significantly reduced cell proliferation compared to cells in the other 2 groups (Figure 2A, 2B). In order to investigate the migration and invasion of post-transfection cells in different groups, the wound healing assay and Transwell assay performed. We found that SKOV3/OVCAR3 cells transfected with the miR-144 mimics showed significantly reduced rates of migratory and invasive capacity compared to cells transfected with 2 control groups (Figure 2C–2E). Also, we know that MMP2 and MMP9 can reflect the metastatic ability of tumor cells. Western blot analysis was carried out to verify the protein levels of MMP2 and

**Figure 1.** The expression of miR-144 in ovarian cancer cell lines. (A) The relative expression level of miR-144 in 2 OC cell lines (SKOV3/OVCAR3) and human ovarian cell line (IOSE80) were detected by qRT-PCR. (B, C) qRT-PCR was used to test the expression of miR-144 detected in OC cells transfected with negative control (NC), miR-NC, and miR-144 mimics.
A. SKOV3

OD value at 570 nm

0.0 0.5 1.0 1.5

24 h 48 h 72 h

NC miR-NC miR-144 mimics

B. OVCAR3

OD value at 570 nm

0.0 0.5 1.0 1.5

24 h 48 h 72 h

NC miR-NC miR-144 mimics

C. Ratio of Wound healing in different groups

Control NC miR-144 mimics

SKOV3

OVCAR3

***

D. Cell migration in different groups

Control NC miR-144 mimics

SKOV3

OVCAR3

***

Han S. et al.: miR-144 in ovarian cancer cells
© Med Sci Monit Basic Res, 2018; 24: 40-46

MOLECULAR BIOLOGY

Indexed in: [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
MMP9, and the results demonstrated they were significantly decreased in miR-144 mimic-transfected cells (Figure 2F, 2G). All these results suggest that miR-144 suppresses ovarian cancer cell growth.

RUNX1 is a target of MiR-144 in OC cells

To investigate the potential role miR-144 played in the growth of OC cells, we performed bioinformatics analysis, which predicted it targets the 3'-UTR of RUNX1 (Figure 3). Next, a dual luciferase reporter system was used to determine if RUNX1 is a direct target of miR-144. As shown in Figure 3B, the luciferase activity of wild-type (WT) RUNX1 3' UTR was dramatically decreased by miR-144 mimics. Moreover, qRT-PCR and Western blot methods both proved that miR-144 regulates RUNX1 at the mRNA and protein levels (Figure 4). Thus, these data suggest that RUNX1 is a direct functional target of miR-144.
**Figure 4.** Upregulated miR-144 expression reduces the expression of RUNX1. (A) The expression of RUNX1 mRNA was determined by qRT-PCR. (B) The expression of RUNX1 protein was measured using Western blot; GAPDH was used as an internal control.

**Discussion**

MicroRNAs (miRNAs) are evolutionarily conserved, small, non-coding RNAs. Recent research has identified multiple miRNAs involved in the pathogenesis of ovarian cancer mainly through regulating tumor cell proliferation, metastasis, invasion, and apoptosis [10]. For instance, miR-132 was reported to inhibit cell proliferation, invasion, and migration in ovarian cancer cells though targeting E2F5 [11]. miR-214 is one of the most significantly deregulated miRNAs in ovarian cancer; induces cell survival through downregulation of PTEN, suggesting that MiR-214 acts as an oncogene in ovarian cancer cells [12]. In addition, miR-199a significantly affects ovarian cancer cell progression via the IKKβ-mediated NF-κB signaling pathway [13]. However, some known oncogenes with therapeutic and biomarker potential are overexpressed in ovarian cancer cells, such as miRNA-21, -92, and -93 [14]. Here, our results indicated that miR-144 expression in ovarian cancers cell lines was clearly decreased. We found that miR-144 suppressed ovarian cancer cell proliferation, migration, and invasion, suggesting that miR-144 could play an important role in ovarian cancer initiation, progression, and metastasis.

MicroRNA-144 (miR-144) is a conservative microRNA that has been reported to be aberrantly expressed in several types of cancers, such as bladder cancer [15], thyroid cancer [16], gastric cancer [17], colorectal cancer [18], and nasopharyngeal carcinoma (NPC). Recently, a report has showed that miR-144 was significantly downregulated in ovarian cancer cells (SKOV3), and inhibited cell proliferation and tumor growth by inhibiting Glut1 expression [19]. However, the role and potential molecular mechanism of miR-144 in ovarian cancer remains unknown. Therefore, MTT assay, wound healing assay, and Transwell invasion assays were performed to investigate the functions of miR-144 in the ovarian cancer cells (SKOV3/OVCOR3). In our studies, all the results demonstrated that there were no significant differences in the data on SKOV3 and OVCOR3 cells. The results indicated that miR-144 positively regulates OC cell proliferation, migration, and invasion in vitro. Our study suggests that miR-144 might be a potential therapeutic target for the treatment of OC.
To further explore the role of miR-144 in OC cell proliferation, migration, and invasion, we first identified the targets using Targetscan7.1, and RUNX1 was selected as a potential target. For ovarian cancer cell line, our dual luciferase reporter assay revealed that RUNX1 is a novel target gene of miR-144. RUNX1, also known as AML1, is a transcription factor that regulates the growth of cells [20]. Previous studies have reported that RUNX1 expression is decreased and serves as an oncogene in lung cancer cells [21]. In the present study, our qRT-PCR and Western blot analysis showed that the miRNA and protein expression levels of RUNX1 were both downregulated in OC cells at 48 h after miR-144 mimic transfection. As mentioned above, the proliferation, migration, and invasion abilities of ovarian cancer cells were inhibited after miR-144 mimic transfection. Based on these results, we speculated that miR-144 suppresses the proliferation, migration, and invasion of ovarian cancer cells though its target gene, RUNX1. However, more studies are needed to determine whether miRNA-144 functions as a suppressor in OC cells through downregulating the expression of RUNX1. We found that miR-144 overexpression can also down-regulate MMP2 and MMP9 expression. As is well known that MMP2 and MMP9 are migration- and invasion-related genes. It has been previously demonstrated that MMP2 and MMP9 are required to promote cancer cell migration and invasion [22], and they have crucial clinical significance for evaluation of progression and prognosis of malignant cancer, including ovarian cancer. Consequently, our results further confirm that miR-144 plays an important role in ovarian cancer migration and invasion.

Conclusions

Our results presented here show that miR-144 expression was decreased in 2 ovarian cancer cell lines compared with a normal ovarian cell line. Additionally, miR-144 can regulate the proliferation, migration, and invasion of ovarian cancer cells, and miR-144 inhibits the growth and progress of ovarian cancer cells by regulating the expression of RUNX1. These results contribute to improved understanding of the molecular mechanism of ovarian cancer development, and suggest that miR-144 and RUNX1 may serve as new therapeutic targets for ovarian cancer. Of course, we need to further explore the potential role of RUNX1 in the growth and progression of OC cells.

Acknowledgements

We thank all of the people who contributed to this paper, especially Yilei Zhang for assistance with the experimental analysis and Xiaowen Liu for valuable discussions.

Conflict of interest

None.

References:

1. Maldonado L, Hoque MO: Epigenomics and ovarian carcinoma. Biomark Med, 2010; 4(4): 543–70
2. Bristow RE: Surgical standards in the management of ovarian cancer. Curr Opin Oncol, 2000; 12: 474–80
3. Harries M, Gore M: Part II: Chemotherapy for epithelial ovarian cancer—treatment of recurrent disease. Lancet Oncol, 2002; 3: 537–45
4. Ambros V: The functions of animal microRNAs. Nature, 2004; 431: 350–55
5. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell, 2004; 116(2): 281–97
6. Wang W, Peng B, Wang D et al: Human tumor microRNA signatures derived from large-scale oligonucleotide microarray datasets. Int J Cancer, 2011; 129: 1624–34
7. Pan Y, Zhang J, Fu H, Shen L: miR-144 functions as a tumor suppressor in breast cancer through inhibiting ZEB1/2-mediated epithelial mesenchymal transition process. Oncotargets Ther, 2016; 9: 6247–55
8. Zhang LY, Lee VH, Wong AM et al: MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN. Carcinogenesis, 2013; 34: 454–63
9. Ren K, Liu QQ, An ZF et al: miR-144 functions as tumor suppressor by targeting PIM1 in gastric cancer. Oncology, 2017; 13: 3028–37
10. Wang Y, Kim S, Kim IM: Regulation of metastasis by microRNAs in ovarian cancer. Front Oncology, 2014; 4: 143
11. Tian H, Hou L, Xiong YM et al: miR-132 targeting EZF5 suppresses cell proliferation, invasion, migration in ovarian cancer cells. Am J Transl Res, 2016; 8(3): 1492–501
12. Yang H, Kong W, He L et al: MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res, 2008; 68(5): 425–33
13. Dai L, Gu L, Di W: miR-199a attenuates endometrial stromal cell invasive-ness through suppression of the IKK/JNK/NF-kB pathway and reduced intereleukin-8 expression. Mol Hum Reprod, 2012; 18(3): 136–45
14. Resnick KE, Alder H, Hagan JP et al: The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol, 2009; 112(1): 55–59
15. Guo Y, Ying L, Tian Y et al: miR-144 downregulation increases bladder cancer cell proliferation by targeting EZH2 and regulating Wnt signaling. FEBS J, 2015; 280: 4531–38
16. Guan H, Liang W, Xie Z et al: Down-regulation of miR-144 promotes thyroid cancer cell invasion by targeting ZEB1 and ZEB2. Endocrine, 2015; 48: 566–74
17. Liu J, Xue H, Zhang J et al: MicroRNA-144 inhibits the metastasis of gastric cancer by targeting MET expression. J Exp Clin Cancer Res, 2015; 34: 35
18. Iwaya T, Yokobori T, Nishidani et al: Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway. Carcinogenesis, 2012; 33: 2391–97
19. Fan JY, Yang Y, Xie JY et al: MicroRNA-144 mediates metabolic shift in ovarian cancer cells by directly targeting Glut1. Tumor Biol, 2017; 37(5): 6855–60
20. Okuda T, Nishimura M, Nakao M, Fujita Y: RUNX1/AML1: A central player in hematopoiesis. Int J Hematol, 2001; 74 (3): 252–57
21. Ramsey J, Butnor K, Peng Z et al: Loss of RUNX1 is associated with aggressive lung adenocarcinomas. J Cell Physiol, 2018; 233(4): 3487–97
22. Wu YF, Zhang J, Zheng Y et al: MicroRNA-216a-3p inhibits the proliferation, migration, and invasion of human gastric cancer cells via targeting RUNX1 and activating the NF-kB signaling pathway. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, 2018; 26: 157–71